DJIA 17,050.75 138.46 0.82%
NASDAQ 4,810.79 19.64 0.41%
S&P 500 2,013.43 17.60 0.88%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)

company name or ticker

Here's Why Alnylam Pharmaceuticals' Stock Crashed Today

Alnylam Pharmaceuticals' stock dropped hard following its second-quarter earnings. Here's why.

ALNY Crosses Below Key Moving Average Level

Benzinga's Top Downgrades

Alnylam Pharmaceuticals (ALNY) Earnings Report: Q2 2015 Conference Call Transcript

Alnylam Pharmaceuticals (ALNY) John M. Maraganore on Q2 2015 Results - Earnings Call Transcript

Alnylam Pharmaceuticals Injects Some Bad News Into Its Earnings Report

Injection-site reactions cause three patients to drop out of a clinical trial for revusiran.

Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)

3 Stocks Pushing The Drugs Industry Downward

First Week of March 2016 Options Trading For Alnylam Pharmaceuticals (ALNY)

An Assessment Of Celgene's Deal For Receptos

See More Articles...